Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1LEVOCARNITINE
(D02176)		1件: Levocarnitine1件: Levocarnitine (D02176) 💬 --3件: 3, 53, 97 💬
2Levocarnitine propyl hydrochloride
(D02176)		1件: Levocarnitine1件: Levocarnitine (D02176) 💬 --1件: 97 💬
3Valproate, Levocarnitine
(D02176)		2件: Levocarnitine,
Valproic acid		2件: Valproic acid ,
Levocarnitine (D02176) 💬 		7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬 		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 3 💬
4Valproic Acid and Levocarnitine
(D02176)		2件: Levocarnitine,
Valproic acid		2件: Valproic acid ,
Levocarnitine (D02176) 💬 		7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬 		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬1件: 3 💬